162 related articles for article (PubMed ID: 21296118)
21. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.
Klein NP; Reisinger KS; Johnston W; Odrljin T; Gill CJ; Bedell L; Dull P
Pediatr Infect Dis J; 2012 Jan; 31(1):64-71. PubMed ID: 22094635
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.
Togashi T; Yamaji M; Thompson A; Giardina PC; Aizawa M; Patterson S; Gruber WC; Scott DA;
Pediatr Infect Dis J; 2013 Sep; 32(9):984-9. PubMed ID: 23538524
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
25. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
[TBL] [Abstract][Full Text] [Related]
26. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.
Ekström N; Väkeväinen M; Verho J; Kilpi T; Käyhty H
Infect Immun; 2007 Apr; 75(4):1794-800. PubMed ID: 17261612
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants.
Rennels MB; Edwards KM; Keyserling HL; Reisinger K; Blatter MM; Quataert SA; Madore DV; Chang I; Malinoski FJ; Hackell JG; Paradiso PR
Pediatr Infect Dis J; 2001 Feb; 20(2):153-9. PubMed ID: 11224833
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs.
van den Dobbelsteen GP; van Dijken HH; Pillai S; van Alphen L
Vaccine; 2007 Mar; 25(13):2491-6. PubMed ID: 17023098
[TBL] [Abstract][Full Text] [Related]
29. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children.
Henckaerts I; Durant N; De Grave D; Schuerman L; Poolman J
Vaccine; 2007 Mar; 25(13):2518-27. PubMed ID: 17034907
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar ) in Korean infants: differences that are found in Asian children.
Kim NH; Lee J; Lee SJ; Lee H; Kim KH; Park SE; Lee HJ
Vaccine; 2007 Nov; 25(45):7858-65. PubMed ID: 17931753
[TBL] [Abstract][Full Text] [Related]
32. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B.
Saeland E; Jakobsen H; Ingolfsdottir G; Sigurdardottir ST; Jonsdottir I
J Infect Dis; 2001 Jan; 183(2):253-260. PubMed ID: 11110649
[TBL] [Abstract][Full Text] [Related]
33. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population.
Millar EV; O'Brien KL; Watt JP; Bronsdon MA; Dallas J; Whitney CG; Reid R; Santosham M
Clin Infect Dis; 2006 Jul; 43(1):8-15. PubMed ID: 16758412
[TBL] [Abstract][Full Text] [Related]
34. [Advances in vaccines and invasive disease in children].
Moraga Llop FA
Rev Esp Quimioter; 2001 Dec; 14(4):319-30. PubMed ID: 11856977
[No Abstract] [Full Text] [Related]
35. The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine.
Balmer P; Borrow R; Arkwright PD
Vaccine; 2007 Aug; 25(34):6321-5. PubMed ID: 17629373
[TBL] [Abstract][Full Text] [Related]
36. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines.
Slack MH; Schapira D; Thwaites RJ; Burrage M; Southern J; Andrews N; Borrow R; Goldblatt D; Miller E
J Infect Dis; 2001 Dec; 184(12):1617-20. PubMed ID: 11740740
[TBL] [Abstract][Full Text] [Related]
37. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine.
Tejedor JC; Omeñaca F; García-Sicilia J; Verdaguer J; Van Esso D; Esporrín C; Molina V; Muro M; Marés J; Enrubia M; Moraga F; García-Corbeira P; Dobbelaere K; Schuerman L;
Pediatr Infect Dis J; 2004 Dec; 23(12):1109-15. PubMed ID: 15626947
[TBL] [Abstract][Full Text] [Related]
39. Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine.
Musher DM; Ceasar H; Kojic EM; Musher BL; Gathe JC; Romero-Steiner S; White AC
J Infect Dis; 2005 Apr; 191(7):1063-7. PubMed ID: 15747240
[TBL] [Abstract][Full Text] [Related]
40. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae.
Trotter CL; McVernon J; Ramsay ME; Whitney CG; Mulholland EK; Goldblatt D; Hombach J; Kieny MP;
Vaccine; 2008 Aug; 26(35):4434-45. PubMed ID: 18617296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
